GLAND.NS(GLAND.NS)
GLAND.NS
Gland Pharma Limited specializes in the development and manufacturing of complex injectable formulations, primarily serving the global market with a strong presence in the US and Europe. Its competitive position is bolstered by a robust portfolio of over 270 products and a state-of-the-art manufacturing facility in Hyderabad, India, which adheres to stringent regulatory standards.
Gland Pharma generates revenue through the sale of generic injectable drugs, leveraging its advanced manufacturing capabilities and regulatory compliance to maintain pricing power. The company's focus on high-barrier-to-entry products allows it to capture significant market share in the injectable segment.
FDA approvals for new injectable products
Expansion of manufacturing capacity in Hyderabad
Market penetration in the US and EU
Pricing dynamics in the generic drug market
Regulatory changes impacting drug approvals and pricing
Technological disruptions in drug manufacturing processes
Intensifying competition from generic manufacturers
Potential market entry of new players with innovative products
Low liquidity risk due to high current ratio (4.68)
Potential risks associated with foreign exchange fluctuations given international operations
moderate - Gland Pharma's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles.
Minimal impact from rising interest rates as the company has low debt levels (Debt/Equity of 0.03), but higher rates could affect overall healthcare spending.
minimal - the company has a strong balance sheet with low debt, reducing reliance on credit markets.
growth - the company shows strong revenue and net income growth, appealing to growth-oriented investors.
moderate - historical volatility is manageable, with a beta around 1.1.